首页> 外文期刊>International journal of clinical rheumatology. >Investigational anti-inflammatory drug demonstrates promising data in hip osteoarthritis
【24h】

Investigational anti-inflammatory drug demonstrates promising data in hip osteoarthritis

机译:研究性抗炎药在髋骨关节炎中显示出令人鼓舞的数据

获取原文
获取原文并翻译 | 示例
           

摘要

A recent randomized study examining the use of the investigational anti-inflammatory drug naproxcinod demonstrated improvements in pain and functioning in patients with hip osteoarthritis. The study was a double-blind, parallel-group, 13-week, multicenter study that was intended to examine the efficacy of naproxcinod compared with placebo and to asses the safety of naproxcinod and its effects on a patient's blood pressure.Naproxcinod is part of the cyclooxygenase-inhibiting nitric oxide donator family of drugs; it was developed to attenuate the adverse effects that can hamper the long-term use of many nonsteroidal anti-inflammatory drugs.
机译:最近一项随机研究检查了抗炎药萘普生的使用情况,该研究表明髋骨关节炎患者的疼痛和功能得到改善。这项研究是一项双盲,平行组,为期13周的多中心研究,旨在检查萘普西诺德与安慰剂相比的疗效,并评估萘普西诺德的安全性及其对患者血压的影响。抑制环氧合酶的一氧化氮供体家族的药物;它被开发来减轻可能妨碍长期使用许多非甾体类抗炎药的不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号